重组流感疫苗与标准剂量流感疫苗在18-64岁成人中的成本效果比较
研究采用决策分析模型从社会角度评估重组流感疫苗(RIV4)相比标准剂量四价流感疫苗(SD-IIV4)在18-64岁成人中的成本效果。结果显示RIV4在18-64岁人群每获得1个质量调整生命年(QALY)需花费94,186美元,50-64岁人群为61,329美元/QALY。RIV4可减少病例、门诊、住院和死亡,但18-64岁人群的成本效果对疫苗有效性绝对差异等参数敏感。
要点
- RIV4在18-64岁成人中每QALY花费94,186美元,50-64岁为61,329美元/QALY。
- 使用RIV4每年可减少病例669,984例、门诊261,293次、住院20,046例和死亡1,018例。
- 死亡减少的多数(59%;597/1018)发生在50-64岁人群。
核心结论
- RIV4相对于SD-IIV4在50-64岁和18-64岁成人中均有效且具成本效果,但18-64岁人群的成本效果对参数的微小变化敏感。
- 由于增强型疫苗带来 substantial 公共卫生效益,卫生系统和政策制定者可选择在特定年龄/风险组(如50-64岁)优先使用产品以最大化成本效益比。
研究设计与样本
- 采用决策分析模型,从社会角度评估RIV4相比SD-IIV4在18-64岁成人中的成本效果,以QALY衡量。
- 模型输入包括基于大型当地卫生系统病历数据的2018-2020年疫苗有效性估计、2019-2020年全国疫苗接种和流感流行病学参数,成本和人群分布拟合至季节。
主要发现
- 在18-64岁成人中,RIV4相比SD-IIV4每获得1个QALY需花费94,186美元。
- 在50-64岁人群中,RIV4相对更具成本效果,每获得1个QALY需花费61,329美元。
- 18-64岁人群的成本效果估计对SD-IIV4与RIV4之间疫苗有效性绝对差异等参数敏感。
- 在18-64岁人群中使用RIV4每年可减少病例669,984例、门诊就诊261,293次、住院20,046例和死亡1,018例。
- 死亡减少的多数(59%;597/1018)发生在50-64岁人群。
临床怎么用
- 作者认为,由于增强型疫苗带来 substantial 公共卫生效益,卫生系统和政策制定者可选择在特定年龄/风险组(如50-64岁)优先使用产品以最大化成本效益比。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Advisory Committee on Immunization Practices (ACIP) uses the Evidence to Recommendations Framework that includes cost-effectiveness analyses (CEA) for determining vaccine recommendations. ACIP's preference for protecting adults ≥ 65 years is enhanced vaccines, including recombinant influenza vaccine (RIV4), adjuvanted or high dose influenza vaccine. Less is known about the CEA of enhanced vaccines for younger adults. METHODS: We used decision analysis modeling from a societal perspective to determine the cost-effectiveness, measured in quality adjusted life years (QALYs), of RIV4 compared with standard dose quadrivalent influenza vaccine (SD-IIV4) in adults 18-64 years old. Model inputs included 2018-2020 vaccine effectiveness (VE) estimates based on medical record data from a large local health system, 2019-2020 national vaccination and influenza epidemic parameters, with costs and population distributions fitted to the season. RESULTS: Among adults ages 18-64 years, RIV4 cost $94,186/QALY gained, compared to SD-IIV4. Among those 50-64 years old, RIV4 was relatively more cost-effective ($61,329/QALY gained). Cost-effectiveness estimates for 18-64-year-olds were sensitive to the absolute difference in VE between SD-IIV4 and RIV4, among other parameters. Use of RIV4 in 18-64-year-olds would result in fewer cases (669,984), outpatient visits (261,293), hospitalizations (20,046) and deaths (1,018) annually. The majority (59 %; 597 of 1018) of the decreases in deaths occurred in the 50-64-year-olds. CONCLUSIONS: While RIV4 was effective and cost-effective relative to SD-IIV4 for both 50-64-year-old and 18-64-year-old adults, cost-effectiveness was sensitive to small changes in parameters among 18-64-year-olds. Because substantial public health benefits occur with enhanced vaccines, health systems and policy makers may opt for preferential product use in select age/risk groups (e.g., 50-64 year olds) to maximize their cost-benefit ratios.
引用
- Nowalk MP, Smith KJ, Raviotta JM, et al. Cost-effectiveness of recombinant influenza vaccine compared with standard dose influenza vaccine in adults 18-64 years of age. Vaccine. 2024. PMID: 38971665. doi:10.1016/j.vaccine.2024.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。